Literature DB >> 9921848

Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community?

J A Freeman1, D W Langdon, J C Hobart, A J Thompson.   

Abstract

OBJECTIVE: To determine the duration and pattern of carry-over of benefits gained after a short period of multidisciplinary inpatient rehabilitation.
BACKGROUND: Few studies have evaluated the outcome of rehabilitation after discharge. Long-term follow-up is required to establish whether gains made during the inpatient stay are sustained over time and in the patient's own environment.
METHODS: Prospective single-group longitudinal study. Fifty consecutive patients with progressive MS undergoing inpatient rehabilitation were followed for 12 months after discharge. Assessments were undertaken on admission (A), at discharge, and subsequently at 3-month intervals for 1 year (1Y) with a battery of measures addressing neurologic status, disability, handicap, quality of life, and emotional well-being. The time taken to return to baseline level was calculated using summary measures, and trends in performance levels were plotted.
RESULTS: Twelve-month data were collected for 92% of patients. Although neurologic status declined (median Expanded Disability Status Scale scores: A = 6.8, 1Y = 8.0), improvements were maintained in disability and handicap for 6 months, emotional well-being for 7 months, and health-related quality of life (physical component) for 10 months.
CONCLUSIONS: The benefits gained from rehabilitation were partly maintained after discharge despite worsening neurologic status. Carry-over of benefits, however, declined over time, reinforcing the need for continuity of care between the inpatient setting and the community.

Entities:  

Mesh:

Year:  1999        PMID: 9921848     DOI: 10.1212/wnl.52.1.50

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

Review 1.  Neurological rehabilitation: from mechanisms to management.

Authors:  A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-12       Impact factor: 10.154

2.  Symptomatic management and rehabilitation in multiple sclerosis.

Authors:  A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

Review 3.  Management of secondary-progressive multiple sclerosis.

Authors:  Gavin Giovannoni
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 4.  Neurorehabilitation in multiple sclerosis--what is the evidence-base?

Authors:  Jürg Kesselring
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 5.  Rehabilitation interventions in multiple sclerosis: an overview.

Authors:  Serafin Beer; Fary Khan; Jürg Kesselring
Journal:  J Neurol       Date:  2012-07-08       Impact factor: 4.849

6.  Rehabilitation challenges in multiple sclerosis.

Authors:  Jack S Burks; George Kim Bigley; Harry Haydon Hill
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

Review 7.  Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials.

Authors:  Cindy J Nowinski; Deborah M Miller; David Cella
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

8.  The impact of inpatient neurorehabilitation on psychological well-being on discharge and at 3 month follow-up.

Authors:  Rory J O'Connor; Stefan J Cano; Alan J Thompson; E Diane Playford
Journal:  J Neurol       Date:  2005-03-08       Impact factor: 4.849

9.  A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment.

Authors:  J Craig; C A Young; M Ennis; G Baker; M Boggild
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

10.  Emerging evidence-based physical rehabilitation for multiple sclerosis - towards an inventory of current content across Europe.

Authors:  Kamila Rasova; Peter Feys; Thomas Henze; Hans van Tongeren; Davide Cattaneo; Johanna Jonsdottir; Alena Herbenova
Journal:  Health Qual Life Outcomes       Date:  2010-07-28       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.